Ivo Abraham, PhD, RN, is a professor in the Department of Pharmacy Practice and Science at R. Ken Coit College of Pharmacy, The University of Arizona.
Revumenib for Rare Acute Leukemias Is Cost-Neutral for Health Plans: Ivo Abraham, PhD, RN
June 26th 2025Revumenib for relapsed/refractory acute leukemias with KMT2A translocation is cost-neutral for health plans, but traditional methods of analysis may not be accurate for rare diseases, said Ivo Abraham, PhD, RN, of The University of Arizona.